661 related articles for article (PubMed ID: 21034217)
21. Selective orexin receptor antagonists.
Lebold TP; Bonaventure P; Shireman BT
Bioorg Med Chem Lett; 2013 Sep; 23(17):4761-9. PubMed ID: 23891187
[TBL] [Abstract][Full Text] [Related]
22. Orexins: looking forward to sleep, back at addiction.
Scammell TE; Saper CB
Nat Med; 2007 Feb; 13(2):126-8. PubMed ID: 17290266
[No Abstract] [Full Text] [Related]
23. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons.
Borgland SL; Storm E; Bonci A
Eur J Neurosci; 2008 Oct; 28(8):1545-56. PubMed ID: 18793323
[TBL] [Abstract][Full Text] [Related]
24. Orexins excite neurons of the rat cerebellar nucleus interpositus via orexin 2 receptors in vitro.
Yu L; Zhang XY; Zhang J; Zhu JN; Wang JJ
Cerebellum; 2010 Mar; 9(1):88-95. PubMed ID: 19921532
[TBL] [Abstract][Full Text] [Related]
25. Characterization of sleep-wake patterns in a novel transgenic mouse line overexpressing human prepro-orexin/hypocretin.
Mäkelä KA; Wigren HK; Zant JC; Sakurai T; Alhonen L; Kostin A; Porkka-Heiskanen T; Herzig KH
Acta Physiol (Oxf); 2010 Mar; 198(3):237-49. PubMed ID: 20003098
[TBL] [Abstract][Full Text] [Related]
26. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
27. Orexins and their receptors: structural aspects and role in peripheral tissues.
Voisin T; Rouet-Benzineb P; Reuter N; Laburthe M
Cell Mol Life Sci; 2003 Jan; 60(1):72-87. PubMed ID: 12613659
[TBL] [Abstract][Full Text] [Related]
28. Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders.
Bonifazi A; Del Bello F; Giorgioni G; Piergentili A; Saab E; Botticelli L; Cifani C; Micioni Di Bonaventura E; Micioni Di Bonaventura MV; Quaglia W
Med Res Rev; 2023 Sep; 43(5):1607-1667. PubMed ID: 37036052
[TBL] [Abstract][Full Text] [Related]
29. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
30. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
31. Putting addiction to bed.
Soares C
Sci Am; 2010 Jul; 303(1):23-4. PubMed ID: 20583657
[No Abstract] [Full Text] [Related]
32. Activation of orexin/hypocretin type 1 receptors stimulates cAMP synthesis in primary cultures of rat astrocytes.
Woldan-Tambor A; Biegańska K; Wiktorowska-Owczarek A; Zawilska JB
Pharmacol Rep; 2011; 63(3):717-23. PubMed ID: 21857082
[TBL] [Abstract][Full Text] [Related]
33. Cell transplantation: a future therapy for narcolepsy?
Arias-Carrión O; Murillo-Rodríguez E
CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):309-14. PubMed ID: 19689312
[TBL] [Abstract][Full Text] [Related]
34. Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement.
Duxon MS; Stretton J; Starr K; Jones DN; Holland V; Riley G; Jerman J; Brough S; Smart D; Johns A; Chan W; Porter RA; Upton N
Psychopharmacology (Berl); 2001 Jan; 153(2):203-9. PubMed ID: 11205420
[TBL] [Abstract][Full Text] [Related]
35. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.
Coleman PJ; Schreier JD; Roecker AJ; Mercer SP; McGaughey GB; Cox CD; Hartman GD; Harrell CM; Reiss DR; Doran SM; Garson SL; Anderson WB; Tang C; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Jul; 20(14):4201-5. PubMed ID: 20610153
[TBL] [Abstract][Full Text] [Related]
37. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation.
Beuckmann CT; Yanagisawa M
J Mol Med (Berl); 2002 Jun; 80(6):329-42. PubMed ID: 12072908
[TBL] [Abstract][Full Text] [Related]
38. Role of orexin input in the diurnal rhythm of locus coeruleus impulse activity.
Gompf HS; Aston-Jones G
Brain Res; 2008 Aug; 1224():43-52. PubMed ID: 18614159
[TBL] [Abstract][Full Text] [Related]
39. High specificity of human orexin receptors for orexins over neuropeptide Y and other neuropeptides.
Holmqvist T; Akerman KE; Kukkonen JP
Neurosci Lett; 2001 Jun; 305(3):177-80. PubMed ID: 11403934
[TBL] [Abstract][Full Text] [Related]
40. Orexin receptor subtype activation and locomotor behaviour in the rat.
Samson WK; Bagley SL; Ferguson AV; White MM
Acta Physiol (Oxf); 2010 Mar; 198(3):313-24. PubMed ID: 19889100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
